Equities

Cyfuse Biomedical KK

4892:TYO

Cyfuse Biomedical KK

Actions
  • Price (JPY)732.00
  • Today's Change26.00 / 3.68%
  • Shares traded61.90k
  • 1 Year change-30.94%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cyfuse Biomedical KK is a Japan-based company mainly engaged in the research, development, manufacture and sale of cell products. The Company is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The Company is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The Company is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.

  • Revenue in JPY (TTM)64.79m
  • Net income in JPY-645.40m
  • Incorporated2010
  • Employees21.00
  • Location
    Cyfuse Biomedical KK5A, ICN Bldg., 2-27-17, HongoMINATO-KU 108-6301JapanJPN
  • Phone+81 364351885
  • Fax+81 364351883
  • Websitehttps://www.cyfusebio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Renascience Inc194.17m-258.34m4.59bn3.00--2.86--23.63-20.32-20.3215.27126.400.089-------11.84---12.49--85.31---133.05------0.1814--93.11--23.07------
Immuno-Biological Laboratories Co., Ltd.788.12m-192.71m4.63bn60.00--4.21--5.87-20.69-20.6984.62118.020.51440.87883.7813,135,280.00-12.58-15.11-14.85-17.6162.0656.66-24.45-50.043.490.4940.1774--22.710.9405-11.97------
Delta-Fly Pharma Inc0.00-1.26bn4.65bn11.00--2.75-----187.93-187.930.00205.250.00----0.00-92.45-53.35-103.56-55.60-------769.75---391.170.00---100.00---37.37------
KAINOS Laboratories, Inc.5.06bn637.97m5.21bn144.007.500.7696.891.03152.41152.411,206.781,486.430.60533.084.55--7.646.929.969.2650.4651.8412.6210.802.43--0.122118.462.711.6012.2810.57-9.8316.36
Solasia Pharma KK617.00m-1.11bn5.22bn24.00--2.50--8.47-6.61-6.613.6710.780.23014.101.9325,708,330.00-41.51-48.57-47.74-58.8354.7871.01-180.39-300.892.91--0.031---43.5014.1856.36------
Kidswell Bio Corp2.43bn-1.42bn5.24bn41.00--6.23--2.15-40.81-40.8168.7921.350.54151.842.47---31.67-57.41-51.25-81.1342.7555.20-58.49-123.521.70-28.910.7559---12.4318.93-116.31------
MEDRx Co Ltd22.57m-770.66m5.71bn22.00--2.78--253.05-20.97-20.970.612847.840.01430.004.221,025,955.00-48.80-58.15-50.27-62.23100.0095.70-3,414.38-1,526.1743.57--0.00---50.3528.6016.04---55.29--
Cyfuse Biomedical KK64.79m-645.40m5.74bn21.00--1.87--88.55-82.27-82.278.26378.390.01530.520213.803,085,095.00-15.19---17.68--61.81---996.19--6.39-81.610.2126---83.68---24.32------
Noile-Immune Biotech Inc316.82m-1.13bn6.32bn28.00--1.11--19.95-26.14-26.147.32131.420.06080.1818--11,314,930.00-21.69---22.60--99.29---356.68--66.04--0.00---49.37---192.28------
DNA Chip Research Inc490.46m-248.29m6.50bn36.00--8.88--13.26-39.09-39.0977.17108.270.52929.843.11---26.79-23.49-32.60-26.7013.5314.28-50.62-54.102.92-2,206.97----49.746.3331.48---15.75--
NIPPON CHEMIPHAR CO., LTD.30.75bn-180.00m6.69bn872.00--0.30695.720.2176-49.89-49.898,520.205,115.780.62682.142.70---0.36890.7482-0.52041.0825.1730.99-0.58871.131.53--0.479150.33-2.57-2.10-153.10--24.62-12.94
Chiome Bioscience Inc682.46m-1.22bn6.76bn51.00--5.46--9.91-24.67-24.6713.7722.000.34414.196.8813,381,650.00-61.51-50.50-79.81-57.3858.4157.53-178.77-224.742.90-513.930.2009--8.1926.241.84------
K Pharma Inc500.00m-221.98m6.96bn15.00--2.42--13.93-18.94-18.9443.04247.430.20954.49--33,333,330.00-9.30---9.83--91.00---44.40--42.60----------166.34------
CellSeed Inc193.68m-892.21m7.08bn35.00--3.40--36.58-29.71-29.716.4764.750.0881.637.625,533,600.00-40.53-49.69-43.83-54.5556.5863.66-460.67-428.6219.14--0.0669--50.39-28.62-11.43--80.73--
Symbio Pharmaceuticals Ltd4.64bn-2.74bn7.16bn109.00--0.9976--1.54-66.88-66.88113.80156.380.54392.765.1442,594,130.00-32.15-19.18-35.33-23.6278.3865.84-59.12-24.3210.43--0.00---44.157.82-266.45--42.39--
Veritas In Silico Inc-100.00bn-100.00bn7.20bn15.00--3.05----------363.52------------------------40.94------101.54--123.38------
Data as of May 17 2024. Currency figures normalised to Cyfuse Biomedical KK's reporting currency: Japanese Yen JPY

Institutional shareholders

0.66%Per cent of shares held by top holders
HolderShares% Held
Nippon Life Insurance Co. (Investment Portfolio)as of 15 Mar 202338.00k0.48%
Asset Management One Co., Ltd.as of 20 Jan 202314.00k0.18%
Fivestar Asset Management Co. Ltd.as of 27 Feb 2023300.000.00%
Data from 25 Sep 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.